#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=5. Fibrin Handling for Bioactive Compounds Delivery
1-1	0-2	5.	_	_	_	_
1-2	3-9	Fibrin	person	new	coref	4-20
1-3	10-18	Handling	_	_	_	_
1-4	19-22	for	_	_	_	_
1-5	23-32	Bioactive	abstract[3]	new[3]	coref	19-10[0_3]
1-6	33-42	Compounds	substance|abstract[3]	new|new[3]	coref	4-1[8_0]
1-7	43-51	Delivery	abstract[3]	new[3]	_	_

#Text=5.1 .
2-1	52-55	5.1	abstract	new	_	_
2-2	56-57	.	_	_	_	_

#Text=Tuning Fibrin Intrinsic Characteristics
3-1	58-64	Tuning	_	_	_	_
3-2	65-71	Fibrin	abstract|abstract[7]	new|new[7]	coref	19-2
3-3	72-81	Intrinsic	abstract|abstract[7]	new|new[7]	_	_
3-4	82-97	Characteristics	abstract[7]	new[7]	_	_

#Text=Bioactive compounds including growth factors , cytokines , drugs , and nucleic acids can be easily entrapped in the fibrin matrix by mixing them with fibrinogen or thrombin .
4-1	98-107	Bioactive	substance[8]	giv[8]	coref	7-8[43_8]
4-2	108-117	compounds	substance[8]	giv[8]	_	_
4-3	118-127	including	substance[8]	giv[8]	_	_
4-4	128-134	growth	substance[8]|abstract[9]|abstract[10]	giv[8]|new[9]|new[10]	ana|coref	4-24[0_10]|20-12[128_9]
4-5	135-142	factors	substance[8]|abstract[9]|abstract[10]	giv[8]|new[9]|new[10]	_	_
4-6	143-144	,	substance[8]|abstract[10]	giv[8]|new[10]	_	_
4-7	145-154	cytokines	substance[8]|abstract[10]|substance	giv[8]|new[10]|new	_	_
4-8	155-156	,	substance[8]|abstract[10]	giv[8]|new[10]	_	_
4-9	157-162	drugs	substance[8]|abstract[10]|substance	giv[8]|new[10]|new	_	_
4-10	163-164	,	substance[8]|abstract[10]	giv[8]|new[10]	_	_
4-11	165-168	and	substance[8]|abstract[10]	giv[8]|new[10]	_	_
4-12	169-176	nucleic	substance[8]|abstract[10]|substance[13]	giv[8]|new[10]|new[13]	_	_
4-13	177-182	acids	substance[8]|abstract[10]|substance[13]	giv[8]|new[10]|new[13]	_	_
4-14	183-186	can	_	_	_	_
4-15	187-189	be	_	_	_	_
4-16	190-196	easily	_	_	_	_
4-17	197-206	entrapped	_	_	_	_
4-18	207-209	in	_	_	_	_
4-19	210-213	the	substance[15]	new[15]	coref	5-4[22_15]
4-20	214-220	fibrin	place|substance[15]	giv|new[15]	coref	5-4
4-21	221-227	matrix	substance[15]	new[15]	_	_
4-22	228-230	by	_	_	_	_
4-23	231-237	mixing	_	_	_	_
4-24	238-242	them	abstract	giv	_	_
4-25	243-247	with	_	_	_	_
4-26	248-258	fibrinogen	substance|substance[18]	new|new[18]	coref|coref	5-14|6-3[29_18]
4-27	259-261	or	substance[18]	new[18]	_	_
4-28	262-270	thrombin	substance[18]|substance	new[18]|new	coref	5-12
4-29	271-272	.	_	_	_	_

#Text=In general , fibrin matrix remains porous regardless the conditions and/or thrombin and fibrinogen ratios .
5-1	273-275	In	_	_	_	_
5-2	276-283	general	abstract	new	_	_
5-3	284-285	,	_	_	_	_
5-4	286-292	fibrin	place|substance[22]	giv|giv[22]	coref|coref	6-13|8-36[0_22]
5-5	293-299	matrix	substance[22]	giv[22]	_	_
5-6	300-307	remains	_	_	_	_
5-7	308-314	porous	_	_	_	_
5-8	315-325	regardless	_	_	_	_
5-9	326-329	the	abstract[23]	new[23]	_	_
5-10	330-340	conditions	abstract[23]	new[23]	_	_
5-11	341-347	and/or	abstract[23]	new[23]	_	_
5-12	348-356	thrombin	abstract[23]|substance|substance[25]|abstract[27]	new[23]|giv|new[25]|new[27]	coref|coref	6-6|11-10[68_25]
5-13	357-360	and	abstract[23]|substance[25]|abstract[27]	new[23]|new[25]|new[27]	_	_
5-14	361-371	fibrinogen	abstract[23]|substance[25]|substance|abstract[27]	new[23]|new[25]|giv|new[27]	coref	6-3[28_0]
5-15	372-378	ratios	abstract[23]|abstract[27]	new[23]|new[27]	_	_
5-16	379-380	.	_	_	_	_

#Text=However , increasing fibrinogen and/or thrombin concentrations densifies the structure of a fibrin gel and reduces its degradation rate , thus slowing down the diffusion of loaded molecules ( e. g. , FGF ) .
6-1	381-388	However	_	_	_	_
6-2	389-390	,	_	_	_	_
6-3	391-401	increasing	substance[28]|substance[29]	giv[28]|giv[29]	_	_
6-4	402-412	fibrinogen	substance[28]|substance[29]	giv[28]|giv[29]	_	_
6-5	413-419	and/or	substance[29]	giv[29]	_	_
6-6	420-428	thrombin	substance[29]|substance|animal[31]	giv[29]|giv|new[31]	coref	11-10
6-7	429-443	concentrations	substance[29]|animal[31]	giv[29]|new[31]	_	_
6-8	444-453	densifies	_	_	_	_
6-9	454-457	the	abstract[32]	new[32]	_	_
6-10	458-467	structure	abstract[32]	new[32]	_	_
6-11	468-470	of	abstract[32]	new[32]	_	_
6-12	471-472	a	abstract[32]|object[34]	new[32]|new[34]	ana	6-17[0_34]
6-13	473-479	fibrin	abstract[32]|abstract|object[34]	new[32]|giv|new[34]	coref	11-3
6-14	480-483	gel	abstract[32]|object[34]	new[32]|new[34]	_	_
6-15	484-487	and	_	_	_	_
6-16	488-495	reduces	_	_	_	_
6-17	496-499	its	object|abstract[37]	giv|new[37]	coref	12-50
6-18	500-511	degradation	abstract|abstract[37]	new|new[37]	coref	10-3[60_0]
6-19	512-516	rate	abstract[37]	new[37]	_	_
6-20	517-518	,	_	_	_	_
6-21	519-523	thus	_	_	_	_
6-22	524-531	slowing	_	_	_	_
6-23	532-536	down	_	_	_	_
6-24	537-540	the	abstract[38]	new[38]	coref	10-13[0_38]
6-25	541-550	diffusion	abstract[38]	new[38]	_	_
6-26	551-553	of	abstract[38]	new[38]	_	_
6-27	554-560	loaded	abstract[38]|substance[39]	new[38]|new[39]	appos	6-30[40_39]
6-28	561-570	molecules	abstract[38]|substance[39]	new[38]|new[39]	_	_
6-29	571-572	(	_	_	_	_
6-30	573-575	e.	abstract[40]	giv[40]	ana	7-13[0_40]
6-31	576-578	g.	abstract[40]	giv[40]	_	_
6-32	579-580	,	abstract[40]	giv[40]	_	_
6-33	581-584	FGF	abstract[40]	giv[40]	_	_
6-34	585-586	)	_	_	_	_
6-35	587-588	.	_	_	_	_

#Text=In addition , the release profile of active compounds is affected by their physicochemical properties including partition coefficient , size and functional groups .
7-1	589-591	In	_	_	_	_
7-2	592-600	addition	_	_	_	_
7-3	601-602	,	_	_	_	_
7-4	603-606	the	abstract[42]	new[42]	_	_
7-5	607-614	release	event|abstract[42]	new|new[42]	coref	11-14[70_0]
7-6	615-622	profile	abstract[42]	new[42]	_	_
7-7	623-625	of	abstract[42]	new[42]	_	_
7-8	626-632	active	abstract[42]|substance[43]	new[42]|giv[43]	coref	9-3[57_43]
7-9	633-642	compounds	abstract[42]|substance[43]	new[42]|giv[43]	_	_
7-10	643-645	is	_	_	_	_
7-11	646-654	affected	_	_	_	_
7-12	655-657	by	_	_	_	_
7-13	658-663	their	abstract|abstract[45]	giv|new[45]	coref	8-4[50_0]
7-14	664-679	physicochemical	abstract[45]	new[45]	_	_
7-15	680-690	properties	abstract[45]	new[45]	_	_
7-16	691-700	including	abstract[45]	new[45]	_	_
7-17	701-710	partition	abstract[45]|event|abstract[47]	new[45]|new|new[47]	_	_
7-18	711-722	coefficient	abstract[45]|abstract[47]	new[45]|new[47]	_	_
7-19	723-724	,	abstract[45]	new[45]	_	_
7-20	725-729	size	abstract[45]|quantity	new[45]|new	_	_
7-21	730-733	and	abstract[45]	new[45]	_	_
7-22	734-744	functional	abstract[45]|person[49]	new[45]|new[49]	ana	8-27[0_49]
7-23	745-751	groups	abstract[45]|person[49]	new[45]|new[49]	_	_
7-24	752-753	.	_	_	_	_

#Text=For example , hydrophilic molecules readily leach out ( e. g. , erythromycin , mitomycin C , fluorouracil etc. ) , while hydrophobic molecules , or those which display a strong chemical affinity for the matrix components , are released more gradually ( e. g. , streptomycin , sulfamethoxazole-trimethoprim , cefazolin , enocitabine etc. ) .
8-1	754-757	For	_	_	_	_
8-2	758-765	example	_	_	_	_
8-3	766-767	,	_	_	_	_
8-4	768-779	hydrophilic	substance[50]	giv[50]	coref	34-6[0_50]
8-5	780-789	molecules	substance[50]	giv[50]	_	_
8-6	790-797	readily	_	_	_	_
8-7	798-803	leach	_	_	_	_
8-8	804-807	out	_	_	_	_
8-9	808-809	(	_	_	_	_
8-10	810-812	e.	_	_	_	_
8-11	813-815	g.	_	_	_	_
8-12	816-817	,	_	_	_	_
8-13	818-830	erythromycin	_	_	_	_
8-14	831-832	,	_	_	_	_
8-15	833-842	mitomycin	_	_	_	_
8-16	843-844	C	person	new	_	_
8-17	845-846	,	_	_	_	_
8-18	847-859	fluorouracil	_	_	_	_
8-19	860-864	etc.	_	_	_	_
8-20	865-866	)	_	_	_	_
8-21	867-868	,	_	_	_	_
8-22	869-874	while	_	_	_	_
8-23	875-886	hydrophobic	substance[52]	new[52]	coref	22-12[144_52]
8-24	887-896	molecules	substance[52]	new[52]	_	_
8-25	897-898	,	_	_	_	_
8-26	899-901	or	_	_	_	_
8-27	902-907	those	person	giv	coref	21-7[136_0]
8-28	908-913	which	_	_	_	_
8-29	914-921	display	_	_	_	_
8-30	922-923	a	abstract[54]	new[54]	coref	20-7[125_54]
8-31	924-930	strong	abstract[54]	new[54]	_	_
8-32	931-939	chemical	abstract[54]	new[54]	_	_
8-33	940-948	affinity	abstract[54]	new[54]	_	_
8-34	949-952	for	abstract[54]	new[54]	_	_
8-35	953-956	the	abstract[54]|object[56]	new[54]|new[56]	_	_
8-36	957-963	matrix	abstract[54]|substance|object[56]	new[54]|giv|new[56]	coref	9-21[59_0]
8-37	964-974	components	abstract[54]|object[56]	new[54]|new[56]	_	_
8-38	975-976	,	_	_	_	_
8-39	977-980	are	_	_	_	_
8-40	981-989	released	_	_	_	_
8-41	990-994	more	_	_	_	_
8-42	995-1004	gradually	_	_	_	_
8-43	1005-1006	(	_	_	_	_
8-44	1007-1009	e.	_	_	_	_
8-45	1010-1012	g.	_	_	_	_
8-46	1013-1014	,	_	_	_	_
8-47	1015-1027	streptomycin	_	_	_	_
8-48	1028-1029	,	_	_	_	_
8-49	1030-1059	sulfamethoxazole-trimethoprim	_	_	_	_
8-50	1060-1061	,	_	_	_	_
8-51	1062-1071	cefazolin	_	_	_	_
8-52	1072-1073	,	_	_	_	_
8-53	1074-1085	enocitabine	_	_	_	_
8-54	1086-1090	etc.	_	_	_	_
8-55	1091-1092	)	_	_	_	_
8-56	1093-1094	.	_	_	_	_

#Text=Thus , some compounds need to be modified chemically to become more hydrophobic , resulting in a prolonged retention within the matrix .
9-1	1095-1099	Thus	_	_	_	_
9-2	1100-1101	,	_	_	_	_
9-3	1102-1106	some	substance[57]	giv[57]	coref	11-17[71_57]
9-4	1107-1116	compounds	substance[57]	giv[57]	_	_
9-5	1117-1121	need	_	_	_	_
9-6	1122-1124	to	_	_	_	_
9-7	1125-1127	be	_	_	_	_
9-8	1128-1136	modified	_	_	_	_
9-9	1137-1147	chemically	_	_	_	_
9-10	1148-1150	to	_	_	_	_
9-11	1151-1157	become	_	_	_	_
9-12	1158-1162	more	_	_	_	_
9-13	1163-1174	hydrophobic	_	_	_	_
9-14	1175-1176	,	_	_	_	_
9-15	1177-1186	resulting	_	_	_	_
9-16	1187-1189	in	_	_	_	_
9-17	1190-1191	a	abstract[58]	new[58]	_	_
9-18	1192-1201	prolonged	abstract[58]	new[58]	_	_
9-19	1202-1211	retention	abstract[58]	new[58]	_	_
9-20	1212-1218	within	abstract[58]	new[58]	_	_
9-21	1219-1222	the	abstract[58]|substance[59]	new[58]|giv[59]	coref	11-4[0_59]
9-22	1223-1229	matrix	abstract[58]|substance[59]	new[58]|giv[59]	_	_
9-23	1230-1231	.	_	_	_	_

#Text=Conversely , a proteolytic degradation may be required to speed up the diffusion process .
10-1	1232-1242	Conversely	_	_	_	_
10-2	1243-1244	,	_	_	_	_
10-3	1245-1246	a	abstract[60]	giv[60]	coref	15-16[111_60]
10-4	1247-1258	proteolytic	abstract[60]	giv[60]	_	_
10-5	1259-1270	degradation	abstract[60]	giv[60]	_	_
10-6	1271-1274	may	_	_	_	_
10-7	1275-1277	be	_	_	_	_
10-8	1278-1286	required	_	_	_	_
10-9	1287-1289	to	_	_	_	_
10-10	1290-1295	speed	_	_	_	_
10-11	1296-1298	up	_	_	_	_
10-12	1299-1302	the	abstract[62]	new[62]	_	_
10-13	1303-1312	diffusion	abstract|abstract[62]	giv|new[62]	_	_
10-14	1313-1320	process	abstract[62]	new[62]	_	_
10-15	1321-1322	.	_	_	_	_

#Text=Lastly , fibrin matrix proteolysis through the action of thrombin or plasmin induces the release of entrapped compounds .
11-1	1323-1329	Lastly	_	_	_	_
11-2	1330-1331	,	_	_	_	_
11-3	1332-1338	fibrin	person|substance[65]	giv|new[65]	coref|coref	12-14[0_65]|12-49
11-4	1339-1345	matrix	substance|substance[65]	giv|new[65]	coref	12-8[73_0]
11-5	1346-1357	proteolysis	substance[65]	new[65]	_	_
11-6	1358-1365	through	substance[65]	new[65]	_	_
11-7	1366-1369	the	substance[65]|abstract[66]	new[65]|new[66]	_	_
11-8	1370-1376	action	substance[65]|abstract[66]	new[65]|new[66]	_	_
11-9	1377-1379	of	substance[65]|abstract[66]	new[65]|new[66]	_	_
11-10	1380-1388	thrombin	substance[65]|abstract[66]|substance|substance[68]	new[65]|new[66]|giv|giv[68]	_	_
11-11	1389-1391	or	substance[65]|abstract[66]|substance[68]	new[65]|new[66]|giv[68]	_	_
11-12	1392-1399	plasmin	substance[65]|abstract[66]|substance[68]|substance	new[65]|new[66]|giv[68]|new	coref	14-5
11-13	1400-1407	induces	_	_	_	_
11-14	1408-1411	the	event[70]	giv[70]	_	_
11-15	1412-1419	release	event[70]	giv[70]	_	_
11-16	1420-1422	of	event[70]	giv[70]	_	_
11-17	1423-1432	entrapped	event[70]|substance[71]	giv[70]|giv[71]	coref	20-23[132_71]
11-18	1433-1442	compounds	event[70]|substance[71]	giv[70]|giv[71]	_	_
11-19	1443-1444	.	_	_	_	_

#Text=In order to restrict this breakdown of the matrix , the co-entrapment of proteolysis inhibitors ( aprotinin , matrix metalloproteinases inhibitors such as galardin ) was investigated . Ahmed et al. identified in their model ( i. e. , chondroprogenitor clonal cell line ) the enzymes responsible for fibrin gel breakdown .
12-1	1445-1447	In	_	_	_	_
12-2	1448-1453	order	_	_	_	_
12-3	1454-1456	to	_	_	_	_
12-4	1457-1465	restrict	_	_	_	_
12-5	1466-1470	this	event[72]	new[72]	coref	12-49[91_72]
12-6	1471-1480	breakdown	event[72]	new[72]	_	_
12-7	1481-1483	of	event[72]	new[72]	_	_
12-8	1484-1487	the	event[72]|substance[73]	new[72]|giv[73]	coref	12-19[0_73]
12-9	1488-1494	matrix	event[72]|substance[73]	new[72]|giv[73]	_	_
12-10	1495-1496	,	_	_	_	_
12-11	1497-1500	the	abstract[74]	new[74]	_	_
12-12	1501-1514	co-entrapment	abstract[74]	new[74]	_	_
12-13	1515-1517	of	abstract[74]	new[74]	_	_
12-14	1518-1529	proteolysis	abstract[74]|substance|object[76]|abstract[77]	new[74]|giv|new[76]|new[77]	ana	12-34[0_77]
12-15	1530-1540	inhibitors	abstract[74]|object[76]|abstract[77]	new[74]|new[76]|new[77]	_	_
12-16	1541-1542	(	abstract[74]|abstract[77]	new[74]|new[77]	_	_
12-17	1543-1552	aprotinin	abstract[74]|abstract[77]|substance	new[74]|new[77]|new	coref	15-6
12-18	1553-1554	,	abstract[74]|abstract[77]	new[74]|new[77]	_	_
12-19	1555-1561	matrix	abstract[74]|abstract[77]|substance|substance[81]	new[74]|new[77]|giv|new[81]	coref	17-9[115_0]
12-20	1562-1580	metalloproteinases	abstract[74]|abstract[77]|abstract|substance[81]	new[74]|new[77]|new|new[81]	coref	13-3[92_0]
12-21	1581-1591	inhibitors	abstract[74]|abstract[77]|substance[81]	new[74]|new[77]|new[81]	_	_
12-22	1592-1596	such	abstract[74]|abstract[77]|substance[81]	new[74]|new[77]|new[81]	_	_
12-23	1597-1599	as	abstract[74]|abstract[77]|substance[81]	new[74]|new[77]|new[81]	_	_
12-24	1600-1608	galardin	abstract[74]|abstract[77]|substance[81]|person	new[74]|new[77]|new[81]|new	coref	15-8[107_0]
12-25	1609-1610	)	abstract[74]|abstract[77]	new[74]|new[77]	_	_
12-26	1611-1614	was	_	_	_	_
12-27	1615-1627	investigated	_	_	_	_
12-28	1628-1629	.	_	_	_	_
12-29	1630-1635	Ahmed	person	new	_	_
12-30	1636-1638	et	_	_	_	_
12-31	1639-1642	al.	_	_	_	_
12-32	1643-1653	identified	_	_	_	_
12-33	1654-1656	in	_	_	_	_
12-34	1657-1662	their	abstract|abstract[85]	giv|new[85]	_	_
12-35	1663-1668	model	abstract[85]	new[85]	_	_
12-36	1669-1670	(	_	_	_	_
12-37	1671-1673	i.	_	_	_	_
12-38	1674-1676	e.	_	_	_	_
12-39	1677-1678	,	_	_	_	_
12-40	1679-1696	chondroprogenitor	object[87]	new[87]	_	_
12-41	1697-1703	clonal	object[87]	new[87]	_	_
12-42	1704-1708	cell	object|object[87]	new|new[87]	_	_
12-43	1709-1713	line	object[87]	new[87]	_	_
12-44	1714-1715	)	_	_	_	_
12-45	1716-1719	the	abstract[88]	new[88]	_	_
12-46	1720-1727	enzymes	abstract[88]	new[88]	_	_
12-47	1728-1739	responsible	abstract[88]	new[88]	_	_
12-48	1740-1743	for	_	_	_	_
12-49	1744-1750	fibrin	abstract|event[91]	giv|giv[91]	coref|coref	13-16|13-16[98_91]
12-50	1751-1754	gel	object|event[91]	giv|giv[91]	_	_
12-51	1755-1764	breakdown	event[91]	giv[91]	_	_
12-52	1765-1766	.	_	_	_	_

#Text=It appeared that metalloproteinases ( MMP-2 , MMP-3 , MMP-9 ) were secreted concomitantly with fibrin hydrogels breakdown .
13-1	1767-1769	It	_	_	_	_
13-2	1770-1778	appeared	_	_	_	_
13-3	1779-1783	that	abstract[92]	giv[92]	appos	13-8[0_92]
13-4	1784-1802	metalloproteinases	abstract[92]	giv[92]	_	_
13-5	1803-1804	(	_	_	_	_
13-6	1805-1810	MMP-2	object	new	_	_
13-7	1811-1812	,	_	_	_	_
13-8	1813-1818	MMP-3	abstract	giv	ana	14-1
13-9	1819-1820	,	_	_	_	_
13-10	1821-1826	MMP-9	substance	new	_	_
13-11	1827-1828	)	_	_	_	_
13-12	1829-1833	were	_	_	_	_
13-13	1834-1842	secreted	_	_	_	_
13-14	1843-1856	concomitantly	_	_	_	_
13-15	1857-1861	with	_	_	_	_
13-16	1862-1868	fibrin	abstract|event[98]	giv|giv[98]	coref|coref	14-12[104_98]|15-16
13-17	1869-1878	hydrogels	substance|event[98]	new|giv[98]	coref	15-17
13-18	1879-1888	breakdown	event[98]	giv[98]	_	_
13-19	1889-1890	.	_	_	_	_

#Text=They also noted high plasmin activity in the conditioned media during hydrogel breakdown .
14-1	1891-1895	They	abstract	giv	ana	15-3
14-2	1896-1900	also	_	_	_	_
14-3	1901-1906	noted	_	_	_	_
14-4	1907-1911	high	abstract[101]	new[101]	coref	29-9[193_101]
14-5	1912-1919	plasmin	person|abstract[101]	giv|new[101]	coref	28-8[180_0]
14-6	1920-1928	activity	abstract[101]	new[101]	_	_
14-7	1929-1931	in	abstract[101]	new[101]	_	_
14-8	1932-1935	the	abstract[101]|organization[102]	new[101]|new[102]	_	_
14-9	1936-1947	conditioned	abstract[101]|organization[102]	new[101]|new[102]	_	_
14-10	1948-1953	media	abstract[101]|organization[102]	new[101]|new[102]	_	_
14-11	1954-1960	during	abstract[101]|organization[102]	new[101]|new[102]	_	_
14-12	1961-1969	hydrogel	abstract[101]|organization[102]|substance|event[104]	new[101]|new[102]|new|giv[104]	_	_
14-13	1970-1979	breakdown	abstract[101]|organization[102]|event[104]	new[101]|new[102]|giv[104]	_	_
14-14	1980-1981	.	_	_	_	_

#Text=Then , they demonstrated that aprotinin and galardin , in combination or separately , prevented fibrin hydrogels degradation .
15-1	1982-1986	Then	_	_	_	_
15-2	1987-1988	,	_	_	_	_
15-3	1989-1993	they	abstract	giv	_	_
15-4	1994-2006	demonstrated	_	_	_	_
15-5	2007-2011	that	_	_	_	_
15-6	2012-2021	aprotinin	substance	giv	_	_
15-7	2022-2025	and	_	_	_	_
15-8	2026-2034	galardin	person[107]	giv[107]	_	_
15-9	2035-2036	,	person[107]	giv[107]	_	_
15-10	2037-2039	in	person[107]	giv[107]	_	_
15-11	2040-2051	combination	person[107]|abstract[108]	giv[107]|new[108]	coref	19-7[121_108]
15-12	2052-2054	or	person[107]|abstract[108]	giv[107]|new[108]	_	_
15-13	2055-2065	separately	person[107]|abstract[108]	giv[107]|new[108]	_	_
15-14	2066-2067	,	_	_	_	_
15-15	2068-2077	prevented	_	_	_	_
15-16	2078-2084	fibrin	person|abstract[111]	giv|giv[111]	coref|coref	17-9|33-7[215_111]
15-17	2085-2094	hydrogels	substance|abstract[111]	giv|giv[111]	_	_
15-18	2095-2106	degradation	abstract[111]	giv[111]	_	_
15-19	2107-2108	.	_	_	_	_

#Text=Figure 4
16-1	2109-2115	Figure	abstract[112]	new[112]	coref	45-1[274_112]
16-2	2116-2117	4	abstract[112]	new[112]	_	_

#Text=summarizes the modifications which can be made on fibrin matrix to regulate the release of entrapped agents .
17-1	2118-2128	summarizes	_	_	_	_
17-2	2129-2132	the	abstract[113]	new[113]	coref	21-4[135_113]
17-3	2133-2146	modifications	abstract[113]	new[113]	_	_
17-4	2147-2152	which	_	_	_	_
17-5	2153-2156	can	_	_	_	_
17-6	2157-2159	be	_	_	_	_
17-7	2160-2164	made	_	_	_	_
17-8	2165-2167	on	_	_	_	_
17-9	2168-2174	fibrin	place|substance[115]	giv|giv[115]	coref	28-33[190_115]
17-10	2175-2181	matrix	substance[115]	giv[115]	_	_
17-11	2182-2184	to	_	_	_	_
17-12	2185-2193	regulate	_	_	_	_
17-13	2194-2197	the	event[116]	new[116]	_	_
17-14	2198-2205	release	event[116]	new[116]	_	_
17-15	2206-2208	of	event[116]	new[116]	_	_
17-16	2209-2218	entrapped	event[116]|person[117]	new[116]|new[117]	coref	19-4[120_117]
17-17	2219-2225	agents	event[116]|person[117]	new[116]|new[117]	_	_
17-18	2226-2227	.	_	_	_	_

#Text=5.2 .
18-1	2228-2231	5.2	abstract	new	_	_
18-2	2232-2233	.	_	_	_	_

#Text=Modifying Fibrin and/or Active Agents for Efficient Combination and Delivery
19-1	2234-2243	Modifying	_	_	_	_
19-2	2244-2250	Fibrin	substance	giv	coref	20-5
19-3	2251-2257	and/or	_	_	_	_
19-4	2258-2264	Active	person[120]	giv[120]	_	_
19-5	2265-2271	Agents	person[120]	giv[120]	_	_
19-6	2272-2275	for	person[120]	giv[120]	_	_
19-7	2276-2285	Efficient	person[120]|abstract[121]	giv[120]|giv[121]	_	_
19-8	2286-2297	Combination	person[120]|abstract[121]	giv[120]|giv[121]	_	_
19-9	2298-2301	and	person[120]	giv[120]	_	_
19-10	2302-2310	Delivery	person[120]|abstract	giv[120]|giv	coref	23-9

#Text=In some instances , fibrin exhibits innate affinity for therapeutics and growth factors but in other cases , the covalent attachment of these compounds to fibrin is considered .
20-1	2311-2313	In	_	_	_	_
20-2	2314-2318	some	time[123]	new[123]	_	_
20-3	2319-2328	instances	time[123]	new[123]	_	_
20-4	2329-2330	,	_	_	_	_
20-5	2331-2337	fibrin	substance	giv	coref	20-26
20-6	2338-2346	exhibits	_	_	_	_
20-7	2347-2353	innate	abstract[125]	giv[125]	_	_
20-8	2354-2362	affinity	abstract[125]	giv[125]	_	_
20-9	2363-2366	for	abstract[125]	giv[125]	_	_
20-10	2367-2379	therapeutics	abstract[125]|substance	giv[125]|new	_	_
20-11	2380-2383	and	abstract[125]	giv[125]	_	_
20-12	2384-2390	growth	abstract[125]|abstract|abstract[128]	giv[125]|new|giv[128]	coref|coref	23-12|23-12[150_128]
20-13	2391-2398	factors	abstract[125]|abstract[128]	giv[125]|giv[128]	_	_
20-14	2399-2402	but	_	_	_	_
20-15	2403-2405	in	_	_	_	_
20-16	2406-2411	other	abstract[129]	new[129]	_	_
20-17	2412-2417	cases	abstract[129]	new[129]	_	_
20-18	2418-2419	,	_	_	_	_
20-19	2420-2423	the	abstract[131]	new[131]	ana	21-1[0_131]
20-20	2424-2432	covalent	abstract|abstract[131]	new|new[131]	coref	38-3
20-21	2433-2443	attachment	abstract[131]	new[131]	_	_
20-22	2444-2446	of	abstract[131]	new[131]	_	_
20-23	2447-2452	these	abstract[131]|substance[132]	new[131]|giv[132]	coref	39-5[239_132]
20-24	2453-2462	compounds	abstract[131]|substance[132]	new[131]|giv[132]	_	_
20-25	2463-2465	to	abstract[131]|substance[132]	new[131]|giv[132]	_	_
20-26	2466-2472	fibrin	abstract[131]|substance[132]|substance	new[131]|giv[132]|giv	coref	24-13
20-27	2473-2475	is	_	_	_	_
20-28	2476-2486	considered	_	_	_	_
20-29	2487-2488	.	_	_	_	_

#Text=This generally requires chemical modifications with reactive functional groups ( thiols , azides ) allowing a stable association .
21-1	2489-2493	This	abstract	giv	coref	27-20[176_0]
21-2	2494-2503	generally	_	_	_	_
21-3	2504-2512	requires	_	_	_	_
21-4	2513-2521	chemical	abstract[135]	giv[135]	coref	37-9[233_135]
21-5	2522-2535	modifications	abstract[135]	giv[135]	_	_
21-6	2536-2540	with	abstract[135]	giv[135]	_	_
21-7	2541-2549	reactive	abstract[135]|person[136]	giv[135]|giv[136]	coref	32-16[207_136]
21-8	2550-2560	functional	abstract[135]|person[136]	giv[135]|giv[136]	_	_
21-9	2561-2567	groups	abstract[135]|person[136]	giv[135]|giv[136]	_	_
21-10	2568-2569	(	_	_	_	_
21-11	2570-2576	thiols	substance	new	_	_
21-12	2577-2578	,	_	_	_	_
21-13	2579-2585	azides	substance	new	_	_
21-14	2586-2587	)	_	_	_	_
21-15	2588-2596	allowing	_	_	_	_
21-16	2597-2598	a	abstract[139]	new[139]	_	_
21-17	2599-2605	stable	abstract[139]	new[139]	_	_
21-18	2606-2617	association	abstract[139]	new[139]	_	_
21-19	2618-2619	.	_	_	_	_

#Text=Then , reduction/hydrolysis reactions or enzymatic cleavage mediate the release of active molecules .
22-1	2620-2624	Then	_	_	_	_
22-2	2625-2626	,	_	_	_	_
22-3	2627-2647	reduction/hydrolysis	event[140]	new[140]	_	_
22-4	2648-2657	reactions	event[140]	new[140]	_	_
22-5	2658-2660	or	_	_	_	_
22-6	2661-2670	enzymatic	abstract|event[142]	new|new[142]	coref	28-21[0_142]
22-7	2671-2679	cleavage	event[142]	new[142]	_	_
22-8	2680-2687	mediate	_	_	_	_
22-9	2688-2691	the	event[143]	new[143]	ana	23-1[0_143]
22-10	2692-2699	release	event[143]	new[143]	_	_
22-11	2700-2702	of	event[143]	new[143]	_	_
22-12	2703-2709	active	event[143]|substance[144]	new[143]|giv[144]	coref	30-6[0_144]
22-13	2710-2719	molecules	event[143]|substance[144]	new[143]|giv[144]	_	_
22-14	2720-2721	.	_	_	_	_

#Text=It was shown that this approach prolongs the delivery phase of growth factors for example .
23-1	2722-2724	It	event	giv	_	_
23-2	2725-2728	was	_	_	_	_
23-3	2729-2734	shown	_	_	_	_
23-4	2735-2739	that	_	_	_	_
23-5	2740-2744	this	event[146]	new[146]	_	_
23-6	2745-2753	approach	event[146]	new[146]	_	_
23-7	2754-2762	prolongs	_	_	_	_
23-8	2763-2766	the	abstract[148]	new[148]	_	_
23-9	2767-2775	delivery	abstract|abstract[148]	giv|new[148]	_	_
23-10	2776-2781	phase	abstract[148]	new[148]	_	_
23-11	2782-2784	of	abstract[148]	new[148]	_	_
23-12	2785-2791	growth	abstract[148]|abstract|abstract[150]	new[148]|giv|giv[150]	coref	35-15
23-13	2792-2799	factors	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
23-14	2800-2803	for	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
23-15	2804-2811	example	abstract[148]|abstract[150]	new[148]|giv[150]	_	_
23-16	2812-2813	.	_	_	_	_

#Text=As another illustration , covalently binding of BMP and RGD sequences to fibrin allows interactions with bone marrow stromal cells through integrin surface receptors that triggered downstream signaling pathways .
24-1	2814-2816	As	_	_	_	_
24-2	2817-2824	another	_	_	_	_
24-3	2825-2837	illustration	_	_	_	_
24-4	2838-2839	,	_	_	_	_
24-5	2840-2850	covalently	object[151]	new[151]	coref	38-3[235_151]
24-6	2851-2858	binding	object[151]	new[151]	_	_
24-7	2859-2861	of	_	_	_	_
24-8	2862-2865	BMP	object|abstract[154]	new|new[154]	_	_
24-9	2866-2869	and	abstract[154]	new[154]	_	_
24-10	2870-2873	RGD	abstract|abstract[154]	new|new[154]	_	_
24-11	2874-2883	sequences	abstract[154]	new[154]	_	_
24-12	2884-2886	to	abstract[154]	new[154]	_	_
24-13	2887-2893	fibrin	abstract[154]|substance	new[154]|giv	coref	27-24
24-14	2894-2900	allows	_	_	_	_
24-15	2901-2913	interactions	abstract[156]	new[156]	coref	32-9[205_156]
24-16	2914-2918	with	abstract[156]	new[156]	_	_
24-17	2919-2923	bone	abstract[156]|object[158]	new[156]|new[158]	_	_
24-18	2924-2930	marrow	abstract[156]|animal|object[158]	new[156]|new|new[158]	_	_
24-19	2931-2938	stromal	abstract[156]|object[158]	new[156]|new[158]	_	_
24-20	2939-2944	cells	abstract[156]|object[158]	new[156]|new[158]	_	_
24-21	2945-2952	through	abstract[156]|object[158]	new[156]|new[158]	_	_
24-22	2953-2961	integrin	abstract[156]|object[158]|person|substance[161]	new[156]|new[158]|new|new[161]	_	_
24-23	2962-2969	surface	abstract[156]|object[158]|place|substance[161]	new[156]|new[158]|new|new[161]	coref	42-16
24-24	2970-2979	receptors	abstract[156]|object[158]|substance[161]	new[156]|new[158]|new[161]	_	_
24-25	2980-2984	that	_	_	_	_
24-26	2985-2994	triggered	_	_	_	_
24-27	2995-3005	downstream	abstract[163]	new[163]	_	_
24-28	3006-3015	signaling	abstract|abstract[163]	new|new[163]	_	_
24-29	3016-3024	pathways	abstract[163]	new[163]	_	_
24-30	3025-3026	.	_	_	_	_

#Text=More sophisticated constructions have been tested .
25-1	3027-3031	More	abstract[164]	new[164]	_	_
25-2	3032-3045	sophisticated	abstract[164]	new[164]	_	_
25-3	3046-3059	constructions	abstract[164]	new[164]	_	_
25-4	3060-3064	have	_	_	_	_
25-5	3065-3069	been	_	_	_	_
25-6	3070-3076	tested	_	_	_	_
25-7	3077-3078	.	_	_	_	_

#Text=Starting from BMP-2 , Schmoekel et al. propose a tripartite fusion protein denoted as TG-pl-BMP-2 .
26-1	3079-3087	Starting	_	_	_	_
26-2	3088-3092	from	_	_	_	_
26-3	3093-3098	BMP-2	object	new	coref	29-6
26-4	3099-3100	,	_	_	_	_
26-5	3101-3110	Schmoekel	person	new	_	_
26-6	3111-3113	et	_	_	_	_
26-7	3114-3117	al.	_	_	_	_
26-8	3118-3125	propose	_	_	_	_
26-9	3126-3127	a	object[168]	new[168]	_	_
26-10	3128-3138	tripartite	object[168]	new[168]	_	_
26-11	3139-3145	fusion	abstract|object[168]	new|new[168]	_	_
26-12	3146-3153	protein	object[168]	new[168]	_	_
26-13	3154-3161	denoted	_	_	_	_
26-14	3162-3164	as	_	_	_	_
26-15	3165-3176	TG-pl-BMP-2	_	_	_	_
26-16	3177-3178	.	_	_	_	_

#Text=Under the control of the blood transglutaminase factor XIIIa , the N-terminal transglutaminase substrate domain ( TG ) provides a covalent attachment to fibrin during coagulation .
27-1	3179-3184	Under	_	_	_	_
27-2	3185-3188	the	abstract[169]	new[169]	_	_
27-3	3189-3196	control	abstract[169]	new[169]	_	_
27-4	3197-3199	of	abstract[169]	new[169]	_	_
27-5	3200-3203	the	abstract[169]|abstract[171]	new[169]|new[171]	coref	28-28[188_171]
27-6	3204-3209	blood	abstract[169]|substance|abstract[171]	new[169]|new|new[171]	_	_
27-7	3210-3226	transglutaminase	abstract[169]|abstract[171]	new[169]|new[171]	_	_
27-8	3227-3233	factor	abstract[169]|abstract[171]	new[169]|new[171]	_	_
27-9	3234-3239	XIIIa	abstract[169]|abstract[171]	new[169]|new[171]	_	_
27-10	3240-3241	,	_	_	_	_
27-11	3242-3245	the	abstract[174]	new[174]	appos	27-17[0_174]
27-12	3246-3256	N-terminal	abstract[174]	new[174]	_	_
27-13	3257-3273	transglutaminase	abstract|abstract[174]	new|new[174]	_	_
27-14	3274-3283	substrate	person|abstract[174]	new|new[174]	coref	28-14
27-15	3284-3290	domain	abstract[174]	new[174]	_	_
27-16	3291-3292	(	_	_	_	_
27-17	3293-3295	TG	abstract	giv	coref	28-11[183_0]
27-18	3296-3297	)	_	_	_	_
27-19	3298-3306	provides	_	_	_	_
27-20	3307-3308	a	abstract[176]	giv[176]	_	_
27-21	3309-3317	covalent	abstract[176]	giv[176]	_	_
27-22	3318-3328	attachment	abstract[176]	giv[176]	_	_
27-23	3329-3331	to	abstract[176]	giv[176]	_	_
27-24	3332-3338	fibrin	abstract[176]|substance	giv[176]|giv	coref	28-34
27-25	3339-3345	during	_	_	_	_
27-26	3346-3357	coagulation	event	new	_	_
27-27	3358-3359	.	_	_	_	_

#Text=In addition , upon the action of cell-activated plasmin , the central plasmin substrate domain ( pl ) gives a cleavage site for the local release of the attached growth factor from the fibrin matrix .
28-1	3360-3362	In	_	_	_	_
28-2	3363-3371	addition	_	_	_	_
28-3	3372-3373	,	_	_	_	_
28-4	3374-3378	upon	_	_	_	_
28-5	3379-3382	the	event[179]	new[179]	_	_
28-6	3383-3389	action	event[179]	new[179]	_	_
28-7	3390-3392	of	event[179]	new[179]	_	_
28-8	3393-3407	cell-activated	event[179]|substance[180]	new[179]|giv[180]	coref	28-13[0_180]
28-9	3408-3415	plasmin	event[179]|substance[180]	new[179]|giv[180]	_	_
28-10	3416-3417	,	_	_	_	_
28-11	3418-3421	the	abstract[183]	giv[183]	appos	28-17[0_183]
28-12	3422-3429	central	abstract[183]	giv[183]	_	_
28-13	3430-3437	plasmin	substance|abstract[183]	giv|giv[183]	_	_
28-14	3438-3447	substrate	person|abstract[183]	giv|giv[183]	_	_
28-15	3448-3454	domain	abstract[183]	giv[183]	_	_
28-16	3455-3456	(	_	_	_	_
28-17	3457-3459	pl	abstract	giv	coref	29-3[192_0]
28-18	3460-3461	)	_	_	_	_
28-19	3462-3467	gives	_	_	_	_
28-20	3468-3469	a	place[186]	new[186]	_	_
28-21	3470-3478	cleavage	event|place[186]	giv|new[186]	_	_
28-22	3479-3483	site	place[186]	new[186]	_	_
28-23	3484-3487	for	_	_	_	_
28-24	3488-3491	the	event[187]	new[187]	_	_
28-25	3492-3497	local	event[187]	new[187]	_	_
28-26	3498-3505	release	event[187]	new[187]	_	_
28-27	3506-3508	of	event[187]	new[187]	_	_
28-28	3509-3512	the	event[187]|abstract[188]	new[187]|giv[188]	_	_
28-29	3513-3521	attached	event[187]|abstract[188]	new[187]|giv[188]	_	_
28-30	3522-3528	growth	event[187]|abstract[188]	new[187]|giv[188]	_	_
28-31	3529-3535	factor	event[187]|abstract[188]	new[187]|giv[188]	_	_
28-32	3536-3540	from	event[187]|abstract[188]	new[187]|giv[188]	_	_
28-33	3541-3544	the	event[187]|abstract[188]|substance[190]	new[187]|giv[188]|giv[190]	coref	31-9[200_190]
28-34	3545-3551	fibrin	event[187]|abstract[188]|place|substance[190]	new[187]|giv[188]|giv|giv[190]	coref	30-9
28-35	3552-3558	matrix	event[187]|abstract[188]|substance[190]	new[187]|giv[188]|giv[190]	_	_
28-36	3559-3560	.	_	_	_	_

#Text=Lastly , the C-terminal human BMP-2 domain displays an osteogenic activity .
29-1	3561-3567	Lastly	_	_	_	_
29-2	3568-3569	,	_	_	_	_
29-3	3570-3573	the	abstract[192]	giv[192]	_	_
29-4	3574-3584	C-terminal	abstract[192]	giv[192]	_	_
29-5	3585-3590	human	abstract[192]	giv[192]	_	_
29-6	3591-3596	BMP-2	abstract|abstract[192]	giv|giv[192]	_	_
29-7	3597-3603	domain	abstract[192]	giv[192]	_	_
29-8	3604-3612	displays	_	_	_	_
29-9	3613-3615	an	abstract[193]	giv[193]	_	_
29-10	3616-3626	osteogenic	abstract[193]	giv[193]	_	_
29-11	3627-3635	activity	abstract[193]	giv[193]	_	_
29-12	3636-3637	.	_	_	_	_

#Text=As an alternative to active molecules derivatization , fibrin functionalization can also be achieved .
30-1	3638-3640	As	_	_	_	_
30-2	3641-3643	an	_	_	_	_
30-3	3644-3655	alternative	_	_	_	_
30-4	3656-3658	to	_	_	_	_
30-5	3659-3665	active	abstract[195]	new[195]	_	_
30-6	3666-3675	molecules	substance|abstract[195]	giv|new[195]	_	_
30-7	3676-3690	derivatization	abstract[195]	new[195]	_	_
30-8	3691-3692	,	_	_	_	_
30-9	3693-3699	fibrin	person|abstract[197]	giv|new[197]	coref|coref	31-10|35-15[226_197]
30-10	3700-3717	functionalization	abstract[197]	new[197]	_	_
30-11	3718-3721	can	_	_	_	_
30-12	3722-3726	also	_	_	_	_
30-13	3727-3729	be	_	_	_	_
30-14	3730-3738	achieved	_	_	_	_
30-15	3739-3740	.	_	_	_	_

#Text=For example , to facilitate BMP interaction with a fibrin matrix , Yang et al.
31-1	3741-3744	For	_	_	_	_
31-2	3745-3752	example	_	_	_	_
31-3	3753-3754	,	_	_	_	_
31-4	3755-3757	to	_	_	_	_
31-5	3758-3768	facilitate	_	_	_	_
31-6	3769-3772	BMP	abstract[198]	new[198]	_	_
31-7	3773-3784	interaction	abstract[198]	new[198]	_	_
31-8	3785-3789	with	abstract[198]	new[198]	_	_
31-9	3790-3791	a	abstract[198]|substance[200]	new[198]|giv[200]	_	_
31-10	3792-3798	fibrin	abstract[198]|place|substance[200]	new[198]|giv|giv[200]	coref	32-4
31-11	3799-3805	matrix	abstract[198]|substance[200]	new[198]|giv[200]	_	_
31-12	3806-3807	,	abstract[198]	new[198]	_	_
31-13	3808-3812	Yang	abstract[198]|person	new[198]|new	_	_
31-14	3813-3815	et	abstract[198]	new[198]	_	_
31-15	3816-3819	al.	abstract[198]	new[198]	_	_

#Text=grafted heparin onto fibrin , this leading to electrostatic interactions between the negative charges of heparin sulfate groups , and the positive charges of BMPs amino acid residues .
32-1	3820-3827	grafted	_	_	_	_
32-2	3828-3835	heparin	substance	new	ana	32-6
32-3	3836-3840	onto	_	_	_	_
32-4	3841-3847	fibrin	object	giv	coref	33-7
32-5	3848-3849	,	_	_	_	_
32-6	3850-3854	this	substance	giv	coref	33-3
32-7	3855-3862	leading	_	_	_	_
32-8	3863-3865	to	_	_	_	_
32-9	3866-3879	electrostatic	abstract[205]	giv[205]	_	_
32-10	3880-3892	interactions	abstract[205]	giv[205]	_	_
32-11	3893-3900	between	abstract[205]	giv[205]	_	_
32-12	3901-3904	the	abstract[205]|object[206]	giv[205]|new[206]	_	_
32-13	3905-3913	negative	abstract[205]|object[206]	giv[205]|new[206]	_	_
32-14	3914-3921	charges	abstract[205]|object[206]	giv[205]|new[206]	_	_
32-15	3922-3924	of	abstract[205]|object[206]	giv[205]|new[206]	_	_
32-16	3925-3932	heparin	abstract[205]|object[206]|person[207]	giv[205]|new[206]|giv[207]	ana	40-1[0_207]
32-17	3933-3940	sulfate	abstract[205]|object[206]|person[207]	giv[205]|new[206]|giv[207]	_	_
32-18	3941-3947	groups	abstract[205]|object[206]|person[207]	giv[205]|new[206]|giv[207]	_	_
32-19	3948-3949	,	abstract[205]	giv[205]	_	_
32-20	3950-3953	and	abstract[205]	giv[205]	_	_
32-21	3954-3957	the	abstract[205]|abstract[208]	giv[205]|new[208]	_	_
32-22	3958-3966	positive	abstract[205]|abstract[208]	giv[205]|new[208]	_	_
32-23	3967-3974	charges	abstract[205]|abstract[208]	giv[205]|new[208]	_	_
32-24	3975-3977	of	abstract[205]|abstract[208]	giv[205]|new[208]	_	_
32-25	3978-3982	BMPs	abstract[205]|abstract[208]|object|substance[211]	giv[205]|new[208]|new|new[211]	coref	33-15[217_0]
32-26	3983-3988	amino	abstract[205]|abstract[208]|substance[211]	giv[205]|new[208]|new[211]	_	_
32-27	3989-3993	acid	abstract[205]|abstract[208]|substance|substance[211]	giv[205]|new[208]|new|new[211]	_	_
32-28	3994-4002	residues	abstract[205]|abstract[208]|substance[211]	giv[205]|new[208]|new[211]	_	_
32-29	4003-4004	.	_	_	_	_

#Text=Interestingly , heparin presence slowed down fibrin degradation , and consequently the release of loaded BMPs .
33-1	4005-4018	Interestingly	_	_	_	_
33-2	4019-4020	,	_	_	_	_
33-3	4021-4028	heparin	plant|substance[213]	giv|new[213]	_	_
33-4	4029-4037	presence	substance[213]	new[213]	_	_
33-5	4038-4044	slowed	_	_	_	_
33-6	4045-4049	down	_	_	_	_
33-7	4050-4056	fibrin	person|abstract[215]	giv|giv[215]	coref	35-13
33-8	4057-4068	degradation	abstract[215]	giv[215]	_	_
33-9	4069-4070	,	_	_	_	_
33-10	4071-4074	and	_	_	_	_
33-11	4075-4087	consequently	event[216]	new[216]	coref	39-16[242_216]
33-12	4088-4091	the	event[216]	new[216]	_	_
33-13	4092-4099	release	event[216]	new[216]	_	_
33-14	4100-4102	of	event[216]	new[216]	_	_
33-15	4103-4109	loaded	event[216]|object[217]	new[216]|giv[217]	_	_
33-16	4110-4114	BMPs	event[216]|object[217]	new[216]|giv[217]	_	_
33-17	4115-4116	.	_	_	_	_

#Text=Similar observations were made with FGF .
34-1	4117-4124	Similar	abstract[218]	new[218]	_	_
34-2	4125-4137	observations	abstract[218]	new[218]	_	_
34-3	4138-4142	were	_	_	_	_
34-4	4143-4147	made	_	_	_	_
34-5	4148-4152	with	_	_	_	_
34-6	4153-4156	FGF	abstract	giv	_	_
34-7	4157-4158	.	_	_	_	_

#Text=Despite positive effects reported in literature , there are several drawbacks to fibrin or growth factors/proteins functionalization .
35-1	4159-4166	Despite	_	_	_	_
35-2	4167-4175	positive	abstract[220]	new[220]	_	_
35-3	4176-4183	effects	abstract[220]	new[220]	_	_
35-4	4184-4192	reported	_	_	_	_
35-5	4193-4195	in	_	_	_	_
35-6	4196-4206	literature	abstract	new	_	_
35-7	4207-4208	,	_	_	_	_
35-8	4209-4214	there	_	_	_	_
35-9	4215-4218	are	_	_	_	_
35-10	4219-4226	several	abstract[222]	new[222]	_	_
35-11	4227-4236	drawbacks	abstract[222]	new[222]	_	_
35-12	4237-4239	to	abstract[222]	new[222]	_	_
35-13	4240-4246	fibrin	abstract[222]|substance	new[222]|giv	coref	41-8
35-14	4247-4249	or	abstract[222]	new[222]	_	_
35-15	4250-4256	growth	abstract[222]|abstract|abstract[226]	new[222]|giv|giv[226]	ana	36-5[0_226]
35-16	4257-4273	factors/proteins	abstract[222]|abstract|abstract[226]	new[222]|new|giv[226]	_	_
35-17	4274-4291	functionalization	abstract[222]|abstract[226]	new[222]|giv[226]	_	_
35-18	4292-4293	.	_	_	_	_

#Text=First of all , it requires specific skills , and it is time consuming and expensive .
36-1	4294-4299	First	_	_	_	_
36-2	4300-4302	of	_	_	_	_
36-3	4303-4306	all	_	_	_	_
36-4	4307-4308	,	_	_	_	_
36-5	4309-4311	it	abstract	giv	ana	36-11
36-6	4312-4320	requires	_	_	_	_
36-7	4321-4329	specific	abstract[228]	new[228]	_	_
36-8	4330-4336	skills	abstract[228]	new[228]	_	_
36-9	4337-4338	,	_	_	_	_
36-10	4339-4342	and	_	_	_	_
36-11	4343-4345	it	abstract	giv	_	_
36-12	4346-4348	is	_	_	_	_
36-13	4349-4353	time	time	new	_	_
36-14	4354-4363	consuming	_	_	_	_
36-15	4364-4367	and	_	_	_	_
36-16	4368-4377	expensive	_	_	_	_
36-17	4378-4379	.	_	_	_	_

#Text=Furthermore , proteins functionality can be altered by these modifications .
37-1	4380-4391	Furthermore	_	_	_	_
37-2	4392-4393	,	_	_	_	_
37-3	4394-4402	proteins	substance|abstract[232]	new|new[232]	_	_
37-4	4403-4416	functionality	abstract[232]	new[232]	_	_
37-5	4417-4420	can	_	_	_	_
37-6	4421-4423	be	_	_	_	_
37-7	4424-4431	altered	_	_	_	_
37-8	4432-4434	by	_	_	_	_
37-9	4435-4440	these	abstract[233]	giv[233]	coref	44-1[273_233]
37-10	4441-4454	modifications	abstract[233]	giv[233]	_	_
37-11	4455-4456	.	_	_	_	_

#Text=Indeed , covalent binding can mask active sites , thus affecting their bioactivity .
38-1	4457-4463	Indeed	_	_	_	_
38-2	4464-4465	,	_	_	_	_
38-3	4466-4474	covalent	abstract|object[235]	giv|giv[235]	_	_
38-4	4475-4482	binding	object[235]	giv[235]	_	_
38-5	4483-4486	can	_	_	_	_
38-6	4487-4491	mask	_	_	_	_
38-7	4492-4498	active	place[236]	new[236]	ana	38-12[0_236]
38-8	4499-4504	sites	place[236]	new[236]	_	_
38-9	4505-4506	,	_	_	_	_
38-10	4507-4511	thus	_	_	_	_
38-11	4512-4521	affecting	_	_	_	_
38-12	4522-4527	their	place|abstract[238]	giv|new[238]	coref	43-11[272_238]
38-13	4528-4539	bioactivity	abstract[238]	new[238]	_	_
38-14	4540-4541	.	_	_	_	_

#Text=As an alternative , non-modified compounds can be internalized into particles , to slow down their release . Wang et al. developed a sophisticated system which could serve to deliver low-molecular weight hydrophilic drugs .
39-1	4542-4544	As	_	_	_	_
39-2	4545-4547	an	_	_	_	_
39-3	4548-4559	alternative	_	_	_	_
39-4	4560-4561	,	_	_	_	_
39-5	4562-4574	non-modified	substance[239]	giv[239]	ana	39-16[0_239]
39-6	4575-4584	compounds	substance[239]	giv[239]	_	_
39-7	4585-4588	can	_	_	_	_
39-8	4589-4591	be	_	_	_	_
39-9	4592-4604	internalized	_	_	_	_
39-10	4605-4609	into	_	_	_	_
39-11	4610-4619	particles	object	new	_	_
39-12	4620-4621	,	_	_	_	_
39-13	4622-4624	to	_	_	_	_
39-14	4625-4629	slow	_	_	_	_
39-15	4630-4634	down	_	_	_	_
39-16	4635-4640	their	substance|event[242]	giv|giv[242]	coref	42-7[0_242]
39-17	4641-4648	release	event[242]	giv[242]	_	_
39-18	4649-4650	.	_	_	_	_
39-19	4651-4655	Wang	person	new	_	_
39-20	4656-4658	et	_	_	_	_
39-21	4659-4662	al.	_	_	_	_
39-22	4663-4672	developed	_	_	_	_
39-23	4673-4674	a	abstract[244]	new[244]	_	_
39-24	4675-4688	sophisticated	abstract[244]	new[244]	_	_
39-25	4689-4695	system	abstract[244]	new[244]	_	_
39-26	4696-4701	which	_	_	_	_
39-27	4702-4707	could	_	_	_	_
39-28	4708-4713	serve	_	_	_	_
39-29	4714-4716	to	_	_	_	_
39-30	4717-4724	deliver	_	_	_	_
39-31	4725-4738	low-molecular	substance[246]	new[246]	_	_
39-32	4739-4745	weight	abstract|substance[246]	new|new[246]	_	_
39-33	4746-4757	hydrophilic	substance[246]	new[246]	_	_
39-34	4758-4763	drugs	substance[246]	new[246]	_	_
39-35	4764-4765	.	_	_	_	_

#Text=They used an antithrombosis drug ( i. e. , Tirofiban® ) as a drug model .
40-1	4766-4770	They	person	giv	_	_
40-2	4771-4775	used	_	_	_	_
40-3	4776-4778	an	substance[248]	new[248]	appos	40-10[0_248]
40-4	4779-4793	antithrombosis	substance[248]	new[248]	_	_
40-5	4794-4798	drug	substance[248]	new[248]	_	_
40-6	4799-4800	(	_	_	_	_
40-7	4801-4803	i.	_	_	_	_
40-8	4804-4806	e.	_	_	_	_
40-9	4807-4808	,	_	_	_	_
40-10	4809-4819	Tirofiban®	substance	giv	coref	40-14
40-11	4820-4821	)	_	_	_	_
40-12	4822-4824	as	_	_	_	_
40-13	4825-4826	a	_	_	_	_
40-14	4827-4831	drug	substance	giv	coref	42-6
40-15	4832-4837	model	_	_	_	_
40-16	4838-4839	.	_	_	_	_

#Text=Drug-loaded liposomes were first encapsulated in a fibrin gel , and then combined to chitosan .
41-1	4840-4851	Drug-loaded	object[251]	new[251]	coref	42-19[0_251]
41-2	4852-4861	liposomes	object[251]	new[251]	_	_
41-3	4862-4866	were	_	_	_	_
41-4	4867-4872	first	_	_	_	_
41-5	4873-4885	encapsulated	_	_	_	_
41-6	4886-4888	in	_	_	_	_
41-7	4889-4890	a	object[253]	new[253]	_	_
41-8	4891-4897	fibrin	abstract|object[253]	giv|new[253]	coref	42-33
41-9	4898-4901	gel	object[253]	new[253]	_	_
41-10	4902-4903	,	_	_	_	_
41-11	4904-4907	and	_	_	_	_
41-12	4908-4912	then	_	_	_	_
41-13	4913-4921	combined	_	_	_	_
41-14	4922-4924	to	_	_	_	_
41-15	4925-4933	chitosan	substance	new	coref	42-25
41-16	4934-4935	.	_	_	_	_

#Text=To document/characterize the in vitro drug release profile , different parameters were studied including the surface charge of liposomes , the pore size of chitosan structure , and the crosslinking degree of fibrin gels .
42-1	4936-4938	To	_	_	_	_
42-2	4939-4960	document/characterize	_	_	_	_
42-3	4961-4964	the	abstract[257]	new[257]	_	_
42-4	4965-4967	in	abstract[257]	new[257]	_	_
42-5	4968-4973	vitro	abstract[257]	new[257]	_	_
42-6	4974-4978	drug	substance|abstract[257]	giv|new[257]	_	_
42-7	4979-4986	release	event|abstract[257]	giv|new[257]	_	_
42-8	4987-4994	profile	abstract[257]	new[257]	_	_
42-9	4995-4996	,	_	_	_	_
42-10	4997-5006	different	abstract[258]	new[258]	_	_
42-11	5007-5017	parameters	abstract[258]	new[258]	_	_
42-12	5018-5022	were	_	_	_	_
42-13	5023-5030	studied	_	_	_	_
42-14	5031-5040	including	_	_	_	_
42-15	5041-5044	the	abstract[260]	new[260]	_	_
42-16	5045-5052	surface	place|abstract[260]	giv|new[260]	_	_
42-17	5053-5059	charge	abstract[260]	new[260]	_	_
42-18	5060-5062	of	abstract[260]	new[260]	_	_
42-19	5063-5072	liposomes	abstract[260]|object	new[260]|giv	_	_
42-20	5073-5074	,	_	_	_	_
42-21	5075-5078	the	abstract[263]	new[263]	_	_
42-22	5079-5083	pore	abstract|abstract[263]	new|new[263]	_	_
42-23	5084-5088	size	abstract[263]	new[263]	_	_
42-24	5089-5091	of	abstract[263]	new[263]	_	_
42-25	5092-5100	chitosan	abstract[263]|person|abstract[265]	new[263]|giv|new[265]	_	_
42-26	5101-5110	structure	abstract[263]|abstract[265]	new[263]|new[265]	_	_
42-27	5111-5112	,	_	_	_	_
42-28	5113-5116	and	_	_	_	_
42-29	5117-5120	the	abstract[267]	new[267]	_	_
42-30	5121-5133	crosslinking	abstract|abstract[267]	new|new[267]	_	_
42-31	5134-5140	degree	abstract[267]	new[267]	_	_
42-32	5141-5143	of	abstract[267]	new[267]	_	_
42-33	5144-5150	fibrin	abstract[267]|person|object[269]	new[267]|giv|new[269]	_	_
42-34	5151-5155	gels	abstract[267]|object[269]	new[267]|new[269]	_	_
42-35	5156-5157	.	_	_	_	_

#Text=All these experimental conditions offered different prolonged releases without altering the composite bioactivity .
43-1	5158-5161	All	abstract[270]	new[270]	_	_
43-2	5162-5167	these	abstract[270]	new[270]	_	_
43-3	5168-5180	experimental	abstract[270]	new[270]	_	_
43-4	5181-5191	conditions	abstract[270]	new[270]	_	_
43-5	5192-5199	offered	_	_	_	_
43-6	5200-5209	different	abstract[271]	new[271]	_	_
43-7	5210-5219	prolonged	abstract[271]	new[271]	_	_
43-8	5220-5228	releases	abstract[271]	new[271]	_	_
43-9	5229-5236	without	_	_	_	_
43-10	5237-5245	altering	_	_	_	_
43-11	5246-5249	the	abstract[272]	giv[272]	_	_
43-12	5250-5259	composite	abstract[272]	giv[272]	_	_
43-13	5260-5271	bioactivity	abstract[272]	giv[272]	_	_
43-14	5272-5273	.	_	_	_	_

#Text=All these modifications are summarized in
44-1	5274-5277	All	abstract[273]	giv[273]	_	_
44-2	5278-5283	these	abstract[273]	giv[273]	_	_
44-3	5284-5297	modifications	abstract[273]	giv[273]	_	_
44-4	5298-5301	are	_	_	_	_
44-5	5302-5312	summarized	_	_	_	_
44-6	5313-5315	in	_	_	_	_

#Text=Figure 4
45-1	5316-5322	Figure	abstract[274]	giv[274]	_	_
45-2	5323-5324	4	abstract[274]	giv[274]	_	_

#Text=.
46-1	5325-5326	.	_	_	_	_
